Atlas Trials

A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

Clinical trial NCT06977880 · COMPLETED

Trial details

NCT number
NCT06977880
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2025-02-19
Primary completion
2026-03-20
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.